Reprint of “Dual blockade of the pro-inflammatory chemokine CCL2 and the homeostatic chemokine CXCL12 is as effective as high dose cyclophosphamide in murine proliferative lupus nephritis”

Devarapu, Satish Kumar and Kumar VR, Santhosh and Rupanagudi, Khader Valli and Kulkarni, Onkar P and Eulberg, Dirk and Klussmann, Sven and Anders, Hans-Joachim (2017) Reprint of “Dual blockade of the pro-inflammatory chemokine CCL2 and the homeostatic chemokine CXCL12 is as effective as high dose cyclophosphamide in murine proliferative lupus nephritis”. In: Clinical Immunology, 185 . pp. 119-127. ISSN 15216616

PDF cli_imm_185_119-127_2017.pdf - Published Version Restricted to Registered users only Download (1MB) | Request a copy

Abstract

Induction therapy of proliferative lupus nephritis still requires the use of unselective immunosuppressive drugs with significant toxicities. In search of more specific drugs with equal efficacy but fewer side effects we considered blocking pro-inflammatory chemokine monocyte chemoattractant protein-1 (MCP-1/CCL2) and homeostatic chemokine stromal cell-derived factor-1 (SDF-1/CXCL12), which both contribute to the onset and progression of proliferative lupus nephritis yet through different mechanisms. We hypothesized that dual antagonism could be as potent on lupus nephritis as the unselective immunosuppressant cyclophosphamide (CYC). We estimated serum levels of CCL2 and CXCL12 in patients with SLE (n = 99) and compared the results with healthy individuals (n = 21). In order to prove our hypothesis we used l-enantiomeric RNA Spiegelmer® chemokine antagonists, i.e. the CCL2-specific mNOX-E36 and the CXCL12-specific NOX-A12 to treat female MRL/lpr mice from week 12 to 20 of age with either anti-CXCL12 or anti-CCL2 alone or both. SLE patients showed elevated serum levels of CCL2 but not of CXCL12. Female MRL/lpr mice treated with dual blockade showed significantly more effective than either monotherapy in preventing proteinuria, immune complex glomerulonephritis, and renal excretory failure and the results are at par with CYC treatment. Dual blockade reduced leukocyte counts and renal IL-6, IL-12p40, CCL-5, CCL-2 and CCR-2 mRNA expression. Dual blockade of CCL2 and CXCL12 can be as potent as CYC to suppress the progression of proliferative lupus nephritis probably because the respective chemokine targets mediate different disease pathomechanisms, i.e. systemic autoimmunity and peripheral tissue inflammation.

Item Type:	Journal Article
Publication:	Clinical Immunology
Publisher:	Academic Press Inc.
Additional Information:	The copyright for this article belongs to the Academic Press Inc.
Keywords:	Aptamer; Autoimmunity; MCP-1; Regeneration; SDF-1; SLE
Department/Centre:	Division of Biological Sciences > Centre for Neuroscience
Date Deposited:	30 May 2022 04:42
Last Modified:	30 May 2022 04:42
URI:	https://eprints.iisc.ac.in/id/eprint/72823

Actions (login required)

View Item